- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03221166
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network
Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications. Thalidomide is a small molecule with immunomodulatory and anti-angiogenetic properties. It is currently approved for the treatment of erythema nodosum leprosum, an immunological complication of leprosy and multiple myeloma. It has also been used in several other inflammatory diseases of the skin and of the mucosal membranes, such as Behcet disease, oropharyngeal ulcers in AIDS, cutaneous lupus, and graft versus host disease. Many case series and one pediatric randomized controlled trial proved the efficacy of thalidomide in the treatment of children with CD refractory to standard treatments. In these patients, clinical remission was achieved in about 50% of the cases and was maintained for a mean time superior of 3 years. Mucosal healing after 52 weeks of treatment was observed in 40% of the patients in clinical remission. Moreover, thalidomide was found to have a steroid-sparing effect and to decrease the need for surgical interventions. The clinical and endoscopic efficacy of thalidomide was also observed in children with failure to respond or intolerance to anti-TNF biological drugs.
The aim of this multicentric prospective randomized controlled is to evaluate the efficacy and safety of thalidomide vs infliximab in changing the natural history of CD in patients with poor prognostic outcome. Moreover, the study will evaluate the immunological and genetical mechanisms of CD, the mechanisms of action thalidomide in CD and will the pharmacokinetics, metabolomics and pharmacogenomics of thalidomide, and their impact on thalidomide safety and effectiveness.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Dipartimento di Pediatria dell'Università di Napoli "Federico II"
-
-
Friuli Venezia Giulia
-
Trieste, Friuli Venezia Giulia, Italy, 34137
- IRCCS Burlo Garofolo
-
-
Liguria
-
Genoa, Liguria, Italy, 16147
- Pediatria III Gastroenterologia ed Endoscopia Digestiva, Istituto Giannina Gaslini
-
-
Lombardia
-
Monza, Lombardia, Italy, 20052
- Fondazione MBBM , Azienda Ospedaliera San Gerardo - Università Milano Bicocca
-
-
Sicilia
-
Messina, Sicilia, Italy, 98124
- Unità di Gastroenterologia Pediatrica e Fibrosi Cistica, Dipartimento di Scienze Pediatriche Mediche e Chirurgiche, Policlinico Universitario
-
-
Toscana
-
Firenze, Toscana, Italy, 50139
- Gastroenterologia e Nutrizione Pediatrica, Azienda Ospedaliero Universitaria Meyer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age at diagnosis <18 years and >=6 years
- New diagnosis of CD based on Porto criteria
- CD with inflammatory phenotype (non-penetrating, non-fistulizing) and with no need for surgery except for perinal fistulas
Presence of at least one of the following risk factors for poor prognosis:
- fistulizing perianal disease
- pan-enteric disease
- disease extension > 60 cm
- severe growth delay (height z-score < -2 DS)
- severe osteoporosis (z score < -2 DS)
- hypoalbuminemia (< 3g/dL) or high C-reactive protein (2 times higher the normal range)
- Acceptance of the Risk Evaluation and Mitigation Strategy (REMS) program for reducing the teratogenic risk.
Exclusion Criteria:
- ongoing pregnancy
- presence of peripheral neuropathy
- HIV
- patients with transplanted organs
- ongoing major infections or other severe diseases
- participation to other experimental studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Thalidomide
Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
|
Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
|
ACTIVE_COMPARATOR: Infliximab
Infliximab is a chimeric monoclonal antibody against TNF alpha
|
Infliximab is a chimeric monoclonal antibody against TNF alpha
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy in inducing mucosal healing
Time Frame: 52 weeks
|
Proportion of patients that achieve mucosal healing, defined by a Simplified Endoscopic Activity Index for CD (SES-CD) ≤ 2.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy in inducing clinical response
Time Frame: 12 weeks
|
Clinical response will be evaluated with the weighted Pediatric Crohn's Disease Activity Index (wPCDAI), defined by a reduction of wPCDAI > 50% from the basal values.
|
12 weeks
|
Efficacy in inducing clinical response
Time Frame: 52 weeks
|
Clinical response will be evaluated with the weighted Pediatric Crohn's Disease Activity Index (wPCDAI), defined by a reduction of wPCDAI > 50% from the basal values.
|
52 weeks
|
Efficacy in inducing clinical remission
Time Frame: 12 weeks
|
Clinical remission will be evaluated with the weighted Pediatric Crohn's Disease Activity Index (wPCDAI), defined by a wPCDAI <12.5.
|
12 weeks
|
Efficacy in inducing clinical remission
Time Frame: 52 weeks
|
Clinical remission will be evaluated with the weighted Pediatric Crohn's Disease Activity Index (wPCDAI), defined by a wPCDAI <12.5.
|
52 weeks
|
Efficacy in reducing the need to change therapy
Time Frame: 12 weeks
|
Evaluation of the proportion of patients that need a therapeutic change
|
12 weeks
|
Efficacy in reducing the need to change therapy
Time Frame: 52 weeks
|
Evaluation of the proportion of patients that need a therapeutic change
|
52 weeks
|
Efficacy in reducing hospitalizations
Time Frame: 52 weeks
|
Evaluation of the proportion of patients that need hospitalization.
|
52 weeks
|
Efficacy in reducing the need for surgery
Time Frame: 52 weeks
|
Evaluation of the proportion of patients that need surgery
|
52 weeks
|
Efficacy in reducing erythrocyte sedimentation rate
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of erythrocyte sedimentation rate (ESR)
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Efficacy in reducing C-reactive protein
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of C-reactive protein (CRP)
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Efficacy in reducing faecal calprotectin
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of faecal calprotectin
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Efficacy in modifying body mass index
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of body mass index, defined as weight (kg)/height (m)^2
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Efficacy in modifying height-for-age z score
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of height-for-age z score
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Efficacy in modifying weight-for-age z score
Time Frame: Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the trend of weight-for-age z score
|
Each time point between enrolment and 52 weeks (0, 4, 8, 14, 26, 38, 52 weeks)
|
Evaluation of the Treatment-Emergent Adverse Events
Time Frame: Between enrolment and 52 weeks
|
Number and type
|
Between enrolment and 52 weeks
|
Direct and indirect costs
Time Frame: 52 weeks
|
Comparison of direct and indirect costs (i.e.
drugs, medical supplies and equipment, laboratory and diagnostic tests, hospitalizations, visits, transportation to and from healthcare facilities, missing work and school days…) between the two groups
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Alessandro Ventura, MD PhD, IRCCS Burlo Garofolo
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Thalidomide
- Infliximab
Other Study ID Numbers
- NET-2013-02355002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Thalidomide
-
Henan Cancer HospitalFirst Affiliated Hospital Xi'an Jiaotong UniversityRecruitingEsophageal Carcinoma | Lung Cancer, Nonsmall CellChina
-
Norwegian University of Science and TechnologyThe Research Council of Norway; Nordic Myeloma Study Group, GermanyCompleted
-
Changzhou No.2 People's HospitalUnknownEsophageal CancerChina
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedAnkylosing SpondylitisChina
-
Shanghai Jiao Tong University School of MedicineChanghai Hospital; Peking Union Medical College Hospital; Shanghai Zhongshan... and other collaboratorsCompletedGastrointestinal Vascular MalformationChina
-
Valme University HospitalUniversity of SevilleUnknown
-
G.V. (Sonny) Montgomery VA Medical CenterUnknownHepatitis C Virus Infection | Infection | Herpesvirus 2, HumanUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Roswell Park Cancer InstituteCompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Graft Versus Host DiseaseUnited States
-
Washington University School of MedicineCelgene CorporationCompleted